Journal of Neural Transmission

, Volume 118, Issue 4, pp 607–612 | Cite as

Substantia nigra hyperechogenicity is a risk marker of Parkinson’s disease: no

Movement Disorders - Original Article

Abstract

During the past two decades, transcranial sonography (TCS) has developed to an increasingly used brain imaging method that visualizes characteristic patterns of basal ganglia alterations in distinct movement disorders. Since the discovery of a characteristic abnormal hyperechogenic appearance of substantia nigra (SN) on TCS in Parkinson’s disease (PD), which is stable during the course of the disease and probably present already in preclinical disease stages, the results of several studies have promoted the idea that this TCS finding in healthy subjects might be a risk marker of PD. The present view summarizes current scientific evidence favouring the idea that the TCS finding of SN hyperechogenicity alone may not be a (strong) risk marker of PD. Especially, it is discussed how reliable this TCS finding is, whether this TCS finding can be regarded as a progression marker or a risk marker of PD, how strongly it may indicate a risk of PD, what else if not an increased risk of PD could be indicated, and which role TCS of SN may finally play in the detection of subjects at risk of PD.

Keywords

Transcranial sonography Substantia nigra Parkinson’s disease Risk marker Preclinical diagnosis 

References

  1. Becker G, Seufert J, Bogdahn U, Reichmann H, Reiners K (1995) Degeneration of substantia nigra in chronic Parkinson’s disease visualized by transcranial color-coded real-time sonography. Neurology 45:182–184PubMedGoogle Scholar
  2. Behnke S, Double KL, Duma S, Broe GA, Guenther V, Becker G, Halliday GM (2007) Substantia nigra echomorphology in the healthy very old: correlation with motor slowing. Neuroimage 34:1054–1059PubMedCrossRefGoogle Scholar
  3. Behnke S, Schroeder U, Dillmann U, Buchholz HG, Schreckenberger M, Fuss G, Reith W, Berg D, Krick CM (2009) Hyperechogenicity of the substantia nigra in healthy controls is related to MRI changes and to neuronal loss as determined by F-Dopa PET. Neuroimage 47:1237–1243PubMedCrossRefGoogle Scholar
  4. Berg D (2007a) Disturbance of iron metabolism as a contributing factor to SN hyperechogenicity in Parkinson’s disease: implications for idiopathic and monogenetic forms. Neurochem Res 32:1646–1654PubMedCrossRefGoogle Scholar
  5. Berg D (2007b) Ultrasound in the (premotor) diagnosis of Parkinson’s disease. Parkinsonism Relat Disord 13(Suppl 3):S429–S433PubMedCrossRefGoogle Scholar
  6. Berg D, Becker G, Zeiler B, Tucha O, Hofmann E, Preier M, Benz P, Jost W, Reiners K, Lange KW (1999) Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 53:1026–1031PubMedGoogle Scholar
  7. Berg D, Siefker C, Ruprecht-Dörfler P, Becker G (2001a) Relationship of substantia nigra echogenicity and motor function in elderly subjects. Neurology 56:13–17PubMedGoogle Scholar
  8. Berg D, Jabs B, Merschdorf U, Beckmann H, Becker G (2001b) Echogenicity of substantia nigra determined by transcranial ultrasound correlates with severity of parkinsonian symptoms induced by neuroleptic therapy. Biol Psychiatry 50:463–467PubMedCrossRefGoogle Scholar
  9. Berg D, Siefker C, Becker G (2001c) Echogenicity of the substantia nigra in Parkinson’s disease and its relation to clinical findings. J Neurol 8:684–689CrossRefGoogle Scholar
  10. Berg D, Merz B, Reiners K, Naumann M, Becker G (2005) Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson’s disease. Mov Disord 20:383–385PubMedCrossRefGoogle Scholar
  11. Berg D, Godau J, Walter U (2008) Transcranial sonography in movement disorders. Lancet Neurol 7:1044–1055PubMedCrossRefGoogle Scholar
  12. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20:415–455PubMedCrossRefGoogle Scholar
  13. Birkmayer W, Hornykiewicz O (1962) Der l-Dioxyphenylalanin (l-DOPA)-Effekt beim Parkinson-Syndrom des Menschen: Zur Pathogenese und Behandlung der Parkinson-Akinese. Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr 203:560–574PubMedGoogle Scholar
  14. Budisić M, Trkanjec Z, Bosnjak J, Lovrencić-Huzjan A, Vuković V, Demarin V (2009) Distinguishing Parkinson’s disease and essential tremor with transcranial sonography. Acta Neurol Scand 119:17–21PubMedCrossRefGoogle Scholar
  15. Doepp F, Plotkin M, Siegel L, Kivi A, Gruber D, Lobsien E, Kupsch A, Schreiber SJ (2008) Brain parenchyma sonography and 123I-FP-CIT SPECT in Parkinson’s disease and essential tremor. Mov Disord 23:405–410PubMedCrossRefGoogle Scholar
  16. Fearnley JM, Lees AJ (1991) Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 114:2283–2301PubMedCrossRefGoogle Scholar
  17. Frigerio R, Fujishiro H, Maraganore DM, Klos KJ, DelleDonne A, Heckman MG, Crook JE, Josephs KA, Parisi JE, Boeve BF, Dickson DW, Ahlskog JE (2009) Comparison of risk factor profiles in incidental Lewy body disease and Parkinson disease. Arch Neurol 66:1114–1119PubMedCrossRefGoogle Scholar
  18. Greffard S, Verny M, Bonnet AM, Beinis JY, Gallinari C, Meaume S, Piette F, Hauw JJ, Duyckaerts C (2006) Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch Neurol 63:584–588PubMedCrossRefGoogle Scholar
  19. Hagenah JM, König IR, Becker B, Hilker R, Kasten M, Hedrich K, Pramstaller PP, Klein C, Seidel G (2007) Substantia nigra hyperechogenicity correlates with clinical status and number of Parkin mutated alleles. J Neurol 254:1407–1413PubMedCrossRefGoogle Scholar
  20. Hagenah J, König IR, Sperner J, Wessel L, Seidel G, Condefer K, Saunders-Pullman R, Klein C, Brüggemann N (2010) Life-long increase of substantia nigra hyperechogenicity in transcranial sonography. Neuroimage 51:28–32PubMedCrossRefGoogle Scholar
  21. Hirsch EC (2006) Altered regulation of iron transport and storage in Parkinson’s disease. J Neural Transm 71(Suppl):201–204CrossRefGoogle Scholar
  22. Hirsch E, Graybiel AM, Agid YA (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson’s disease. Nature 334:345–348PubMedCrossRefGoogle Scholar
  23. Hoeppner J, Prudente-Morrissey L, Herpertz SC, Benecke R, Walter U (2009) Substantia nigra hyperechogenicity in depressive subjects relates to motor asymmetry and impaired word fluency. Eur Arch Psychiatry Clin Neurosci 259:92–97PubMedCrossRefGoogle Scholar
  24. Huang YW, Jeng JS, Tsai CF, Chen LL, Wu RM (2007) Transcranial imaging of substantia nigra hyperechogenicity in a Taiwanese cohort of Parkinson’s disease. Mov Disord 22:550–555PubMedCrossRefGoogle Scholar
  25. Jenner P (1992) What process causes nigral cell death in Parkinson’s disease? Neurol Clin 10:387–403Google Scholar
  26. Kim JY, Kim ST, Jeon SH, Lee WY (2007) Midbrain transcranial sonography in Korean patients with Parkinson’s disease. Mov Disord 22:1922–1926PubMedCrossRefGoogle Scholar
  27. Kolevski G, Petrov I, Petrova V (2007) Transcranial sonography in the evaluation of Parkinson disease. J Ultrasound Med 26:509–512PubMedGoogle Scholar
  28. Krauel K, Feldhaus HC, Simon A, Rehe C, Glaser M, Flechtner HH, Heinze HJ, Niehaus L (2010) Increased echogenicity of the substantia nigra in children and adolescents with attention-deficit/hyperactivity disorder. Biol Psychiatry 68:352–358PubMedCrossRefGoogle Scholar
  29. Mijajlović M, Dragasević N, Stefanova E, Petrović I, Svetel M, Kostić VS (2008) Transcranial sonography in spinocerebellar ataxia type 2. J Neurol 255:1164–1167PubMedCrossRefGoogle Scholar
  30. Okawa M, Miwa H, Kajimoto Y, Hama K, Morita S, Nakanishi I, Kondo T (2007) Transcranial sonography of the substantia nigra in Japanese patients with Parkinson’s disease or atypical parkinsonism: clinical potential and limitations. Intern Med 46:1527–1531PubMedCrossRefGoogle Scholar
  31. Parent M, Parent A (2010) Substantia nigra and Parkinson’s disease: a brief history of their long and intimate relationship. Can J Neurol Sci 37:313–319PubMedGoogle Scholar
  32. Postert T, Lack B, Kuhn W, Jergas M, Andrich J, Braun B, Przuntek H, Sprengelmeyer R, Agelink M, Büttner T (1999) Basal ganglia alterations and brain atrophy in Huntington’s disease depicted by transcranial real time sonography. J Neurol Neurosurg Psychiatry 67:457–462PubMedCrossRefGoogle Scholar
  33. Ressner P, Skoloudík D, Hlustík P, Kanovský P (2007) Hyperechogenicity of the substantia nigra in Parkinson’s disease. J Neuroimaging 17:164–167PubMedCrossRefGoogle Scholar
  34. Rhodes SL, Ritz B (2008) Genetics of iron regulation and the possible role of iron in Parkinson’s disease. Neurobiol Dis 32:183–195PubMedCrossRefGoogle Scholar
  35. Riederer P, Wuketich S (1976) Time course of nigrostriatal degeneration in Parkinson’s disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm 38:277–301PubMedCrossRefGoogle Scholar
  36. Ruprecht-Dörfler P, Klotz P, Becker G, Berg D (2007) Substantia nigra hyperechogenicity correlates with subtle motor dysfunction in tap dancers. Parkinsonism Relat Disord 13:362–364PubMedCrossRefGoogle Scholar
  37. Saunders-Pullman R, Stanley K, Brüggemann N, Raymond D, San Luciano M, Wang C, Klein C, Lubarr N, Ozelius L, Bressman SB, Hagenah J (2010) Substantia nigra hyperechogenicity in DYT6 dystonia: a pilot study. Parkinsonism Relat Disord 16:420–422PubMedCrossRefGoogle Scholar
  38. Schmidauer C, Sojer M, Seppi K, Stockner H, Högl B, Biedermann B, Brandauer E, Peralta CM, Wenning GK, Poewe W (2005) Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndrome. Ann Neurol 58:630–634PubMedCrossRefGoogle Scholar
  39. Schweitzer KJ, Hilker R, Walter U, Burghaus L, Berg D (2006) Substantia nigra hyperechogenicity as a marker of predisposition and slower progression in Parkinson’s disease. Mov Disord 21:94–98PubMedCrossRefGoogle Scholar
  40. Skoloudík D, Fadrná T, Bártová P, Langová K, Ressner P, Zapletalová O, Hlustík P, Herzig R, Kannovský P (2007) Reproducibility of sonographic measurement of the substantia nigra. Ultrasound Med Biol 33:1347–1352PubMedCrossRefGoogle Scholar
  41. Snyder AM, Connor JR (2009) Iron, the substantia nigra and related neurological disorders. Biochim Biophys Acta 1790:606–614PubMedGoogle Scholar
  42. Sommer U, Hummel T, Cormann K, Mueller A, Frasnelli J, Kropp J, Reichmann H (2004) Detection of presymptomatic Parkinson’s disease: combining smell tests, transcranial sonography, and SPECT. Mov Disord 19:1196–1202PubMedCrossRefGoogle Scholar
  43. Spiegel J, Behnke S, Fuss G, Becker G, Dillmann U (2005) Echogenic substantia nigra in patients with orthostatic tremor. J Neural Transm 112:915–920PubMedCrossRefGoogle Scholar
  44. Spiegel J, Hellwig D, Möllers MO, Behnke S, Jost W, Fassbender K, Samnick S, Dillmann U, Becker G, Kirsch CM (2006) Transcranial sonography and [123I]FP-CIT SPECT disclose complementary aspects of Parkinson’s disease. Brain 129:1188–1193PubMedCrossRefGoogle Scholar
  45. Stockner H, Sojer M, KS K, Mueller J, Wenning GK, Schmidauer C, Poewe W (2007) Midbrain sonography in patients with essential tremor. Mov Disord 22:414–417PubMedCrossRefGoogle Scholar
  46. Stockner H, Iranzo A, Seppi K, Serradell M, Gschliesser V, Sojer M, Valldeoriola F, Molinuevo JL, Frauscher B, Schmidauer C, Santamaria J, Högl B, Tolosa E, Poewe W, SINBAR (Sleep Innsbruck Barcelona) Group (2009) Midbrain hyperechogenicity in idiopathic REM sleep behavior disorder. Mov Disord 24:1906–1909PubMedCrossRefGoogle Scholar
  47. Tsai CF, Wu RM, Huang YW, Chen LL, Yip PK, Jeng JS (2007) Transcranial color-coded sonography helps differentiation between idiopathic Parkinson’s disease and vascular parkinsonism. J Neurol 254:501–507PubMedCrossRefGoogle Scholar
  48. Unger MM, Möller JC, Stiasny-Kolster K, Mankel K, Berg D, Walter U, Hoeffken H, Mayer G, Oertel WH (2008) Assessment of idiopathic rapid-eye-movement sleep behavior disorder by transcranial sonography, olfactory function test, and FP-CIT-SPECT. Mov Disord 23:596–599PubMedCrossRefGoogle Scholar
  49. van de Loo S, Walter U, Behnke S, Hagenah J, Lorenz M, Sitzer M, Hilker R, Berg D (2010) Reproducibility and diagnostic accuracy of substantia nigra sonography for the diagnosis of Parkinson’s disease. J Neurol Neurosurg Psychiatry 81:1087–1092PubMedCrossRefGoogle Scholar
  50. Walter U (2009) Transcranial brain sonography findings in Parkinson’s disease: implications for pathogenesis, early diagnosis and therapy. Expert Rev Neurother 9:835–846PubMedCrossRefGoogle Scholar
  51. Walter U, Wittstock M, Benecke R, Dressler D (2002) Substantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson’s disease. J Neural Transm 109:191–196PubMedCrossRefGoogle Scholar
  52. Walter U, Klein C, Hilker R, Benecke R, Pramstaller PP, Dressler D (2004a) Brain parenchyma sonography detects preclinical parkinsonism. Mov Disord 19:1445–1449PubMedCrossRefGoogle Scholar
  53. Walter U, Dressler D, Wolters A, Probst T, Grossmann A, Benecke R (2004b) Sonographic discrimination of corticobasal degeneration vs progressive supranuclear palsy. Neurology 63:504–509PubMedGoogle Scholar
  54. Walter U, Krolikowski K, Tarnacka B, Benecke R, Czlonkowska A, Dressler D (2005) Sonographic detection of basal ganglia lesions in asymptomatic and symptomatic Wilson disease. Neurology 64:1726–1732PubMedCrossRefGoogle Scholar
  55. Walter U, Dressler D, Wolters A, Wittstock M, Greim B, Benecke R (2006) Sonographic discrimination of dementia with Lewy bodies and Parkinson’s disease with dementia. J Neurol 253:448–454PubMedCrossRefGoogle Scholar
  56. Walter U, Behnke S, Eyding J, Niehaus L, Postert T, Seodel G, Berg D (2007a) Transcranial brain parenchyma sonography in movement disorders: state of the art. Ultrasound Med Biol 33:15–25PubMedCrossRefGoogle Scholar
  57. Walter U, Hoeppner J, Prudente-Morrissey L, Horowski S, Herpertz SC, Benecke R (2007b) Parkinson’s disease-like midbrain sonography abnormalities are frequent in depressive disorders. Brain 130:1799–1807PubMedCrossRefGoogle Scholar
  58. Walter U, Dressler D, Wolters A, Wittstock M, Benecke R (2007c) Transcranial brain sonography findings in clinical subgroups of idiopathic Parkinson’s disease. Mov Disord 22:48–54PubMedCrossRefGoogle Scholar
  59. Walter U, Dressler D, Probst T, Wolters A, Abu-Mugheisib M, Wittstock M, Benecke R (2007d) Transcranial brain sonography findings in discriminating between parkinsonism and idiopathic Parkinson disease. Arch Neurol 64:1635–1640PubMedCrossRefGoogle Scholar
  60. Walter U, Kanowski M, Kaufmann J, Grossmann A, Benecke R, Niehaus L (2008) Contemporary ultrasound systems allow high-resolution transcranial imaging of small echogenic deep intracranial structures similarly as MRI: a phantom study. Neuroimage 40:551–558PubMedCrossRefGoogle Scholar
  61. Walter U, Wagner S, Horowski S, Benecke R, Zettl UK (2009) Transcranial brain sonography findings predict disease progression in multiple sclerosis. Neurology 73:1010–1017PubMedCrossRefGoogle Scholar
  62. Weise D, Lorenz R, Schliesser M, Schirbel A, Reiners K, Classen J (2009) Substantia nigra echogenicity: a structural correlate of functional impairment of the dopaminergic striatal projection in Parkinson’s disease. Mov Disord 24:1669–1675PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.Department of NeurologyUniversity of RostockRostockGermany

Personalised recommendations